BR112021018540A2 - Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente - Google Patents

Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente

Info

Publication number
BR112021018540A2
BR112021018540A2 BR112021018540A BR112021018540A BR112021018540A2 BR 112021018540 A2 BR112021018540 A2 BR 112021018540A2 BR 112021018540 A BR112021018540 A BR 112021018540A BR 112021018540 A BR112021018540 A BR 112021018540A BR 112021018540 A2 BR112021018540 A2 BR 112021018540A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical formulations
forming
breast
patient
Prior art date
Application number
BR112021018540A
Other languages
English (en)
Portuguese (pt)
Inventor
Angela Spangenberg
Dave Miller
Williams Robert Iii
Urvi Gala
Original Assignee
Univ Texas
Dispersol Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Dispersol Technologies Llc filed Critical Univ Texas
Publication of BR112021018540A2 publication Critical patent/BR112021018540A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112021018540A 2019-03-18 2020-03-17 Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente BR112021018540A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820076P 2019-03-18 2019-03-18
US201962942111P 2019-11-30 2019-11-30
PCT/US2020/023066 WO2020190900A1 (en) 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof

Publications (1)

Publication Number Publication Date
BR112021018540A2 true BR112021018540A2 (pt) 2021-11-30

Family

ID=72521270

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018540A BR112021018540A2 (pt) 2019-03-18 2020-03-17 Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente

Country Status (9)

Country Link
US (1) US20220362264A1 (https=)
EP (1) EP3941478A4 (https=)
JP (1) JP2022525425A (https=)
CN (1) CN113825514A (https=)
AU (1) AU2020240017A1 (https=)
BR (1) BR112021018540A2 (https=)
CA (1) CA3133620A1 (https=)
IL (1) IL286416A (https=)
WO (1) WO2020190900A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738369B1 (ko) * 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF

Also Published As

Publication number Publication date
AU2020240017A1 (en) 2021-11-04
US20220362264A1 (en) 2022-11-17
WO2020190900A1 (en) 2020-09-24
EP3941478A1 (en) 2022-01-26
JP2022525425A (ja) 2022-05-13
IL286416A (en) 2021-10-31
EP3941478A4 (en) 2022-12-28
WO2020190900A8 (en) 2021-10-14
CN113825514A (zh) 2021-12-21
CA3133620A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
BR112021026854A2 (pt) Extrato de cânhamo para tratamento da dor, câncer e epilepsia em animais
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
BR112018013853A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
BR112016014830A2 (pt) Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
BR112017009986A2 (pt) métodos para tratar indivíduos com síndrome de prader-willi ou síndrome de smith-magenis
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016006688A (es) Inhibidores tetraciclicos de autotaxina.
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
BR112021018540A2 (pt) Formulações farmacêuticas, métodos de formação destas, comprimido para administração oral e métodos de tratamento de câncer de próstata, mama e glândula salivar em um paciente
CY1125361T1 (el) Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
MX394957B (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
BR112021021787A2 (pt) Terapias de combinação
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.